Biologic treatments for systemic rheumatic diseases.
Many rheumatologic disorders, most notably Sjögren's syndrome, are associated with dental complications and in some cases oral diseases may trigger or drive connective tissue disease. During the past three decades the treatment in rheumatology was revolutionized by the introduction of disease-modifying anti-rheumatic drugs. Advances in our understanding of the pathogenesis of rheumatic diseases have led to the discovery of critical mechanisms of inflammation and autoimmunity and the invention of new target-specific biologic agents. In this review, we will summarize the current state of biologic therapies in rheumatology and discuss the implications of these on oral health and disease.
Shirota
Y
Y
Sjögren's Syndrome Clinic, Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA.
Illei
G G
GG
Nikolov
N P
NP
D000069594:Abatacept; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D053264:B-Cell Activating Factor / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates / Q000276:immunology; D007155:Immunologic Factors / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000276:immunology; D007378:Interleukins / Q000276:immunology; D008213:Lymphocyte Activation; D012216:Rheumatic Diseases / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology; D012859:Sjogren's Syndrome / Q000188:drug therapy / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D053264:B-Cell Activating Factor; D018796:Immunoconjugates; D007155:Immunologic Factors; D016898:Interferon-alpha; D007378:Interleukins; D051918:Sialic Acid Binding Ig-like Lectin 2; D014409:Tumor Necrosis Factor-alpha; D000069594:Abatacept